Skip to menu Skip to content Skip to footer
Professor Victoria Atkinson
Professor

Victoria Atkinson

Email: 

Overview

Background

Associate Professor Victoria Atkinson is both a Senior Medical Oncologist and a Principal Investigator for clinical trials in the adjuvant and metastatic setting at the Princess Alexandra Hospital and Greenslopes Private Hospital (in collaboration with Gallipoli Medical Research Foundation). Additionally, she is an Associate Professor with the University of Queensland, Clinical School of Medicine. Associate Professor Atkinson’s research interests are in the field of Oncology, and she has extensive experience in targeted-therapies and immunotherapies. Her main research interests are melanoma and gastro-intestinal oncology. Associate Professor Atkinson is passionate about trying to improve outcome for all patients with advanced melanoma as well as advanced gastro-intestinal cancers.

Associate Professor Atkinson has been involved in the clinical development of the current targeted and immunotherapies in melanoma over the past decade bringing these therapies into clinical practice. She has been involved in advocating for patient access to these therapies for patients in Queensland and Australia from guidelines through to reimbursement policies. These therapies have revolutionised the lives of patients and brought about the longest median overall survival for advanced melanoma. However there still remains significant work to be done in therapy resistant disease and she continues to work with therapies towards overcoming resistance.

In the past 5 years, Associate Professor Atkinson has been an Invited Speaker at 22 national and international meetings including Medical Oncology Group of Australia ASM Immunotherapy Symposium, New Zealand Society for Medical Oncology meeting and the Society for Melanoma Research congress. A/Prof Atkinson has published 82 publications, 31 oral abstracts and 65 posters. Associate Professor Atkinson is actively involved in the research supervision of her basic and advanced trainees, and resident medical officers who demonstrate interest in a project. She has supervised trainees to complete their research projects and supported 6 Australian research poster presentations, and 10 international research poster presentations.

She is passionate and motivated to continue to change practice by bringing clinically important and relevant trials to Queensland and to mentor trainees and junior consultants to continue this tradition.

Availability

Professor Victoria Atkinson is:
Available for supervision

Research interests

  • Oncology

  • Melanoma

  • Gastro-intestinal oncology

  • Patient outcomes

Works

Search Professor Victoria Atkinson’s works on UQ eSpace

113 works between 2011 and 2024

101 - 113 of 113 works

2015

Journal Article

Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix

Sparks, David S., Morris, Bradley, Xu, Wen, Fulton, Jessica, Atkinson, Victoria, Meade, Brian and Lutton, Nicholas (2015). Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix. International Surgery, 100 (1), 21-28. doi: 10.9738/INTSURG-D-14-00089.1

Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix

2015

Journal Article

Nivolumab in Previously Untreated Melanoma without a BRAF mutation

Robert, Caroline, Long, Georgina, Brady, Benjamin, Dutriaux, Caroline, Miao, Michele, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinsk-Warzocha, Ewa, Savage, Kerry, Hernberg, Michaela, Lebbe, Cleste, Charles, Julie, Mihalcioiu, Caitlin, Chiarion-Sileni, Vanna, Mauch, Conrelia, Cognetti, Francesco, Arance, Ana, Schmidt, Kenrik, Schadendorf, Dirk, Gogas, Helen, Lundgren-Erikkson, Lotta, Horak, Christine, Sharkey, Brian, Waxman, Ian, Atkinson, Victoria and Ascierto, Paolo (2015). Nivolumab in Previously Untreated Melanoma without a BRAF mutation. The New England Journal of Medicine, 372 (4), 320-330. doi: 10.1056/NEJMoa1412082

Nivolumab in Previously Untreated Melanoma without a BRAF mutation

2015

Journal Article

Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.

Gorayski, Peter, Dzienis, Marcin, Foote, Matthew, Atkinson, Victoria, Burmeister, Elizabeth and Burmeister, Bryan (2015). Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.. Asia Pacific Journal of Oncology, 13 (2), E117-E123. doi: 10.1111/ajco.12345

Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.

2015

Conference Publication

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

Privthviraj, Prashanth, McArthur, Grant, Atkinson, Victoria, Parente, Phillip, Andrews, Miles Cameron, Parakh, Sagun, Cebon, Jonathon and Klein, Oliver (2015). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

2015

Conference Publication

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.

Larkin, James M. G., Yan, Yibing, McArthur, Grant A., Ascierto, Paolo Antonio, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev V., Stroyakovskiy, Daniil, Thomas, Luc, De La Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Wongchenko, Matthew, Rooney, Isabelle Anne, Chang, Ilsung, Hack, Stephen Paul, Dreno, Brigitte and Ribas, Antoni (2015). Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.. American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology.

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.

2014

Journal Article

Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma

Larkin, James, Ascierto, Paolo, Dren, Brigette, Atkinson, Victoria, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Sovak, Mika, Chang, Ilsung, Choong, Nicholas, Hack, Stephen, McArthur, Grant A. and Ribas, Antoni (2014). Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma. The New England Journal of Medicine, 371 (20), 1867-1876. doi: 10.1056/NEJMoa1408868

Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma

2014

Journal Article

BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib

McClenahan, Phil, Lin, Lynlee L., Tan, Jean-Marie, Flewell-Smith, Ross, Schaider, Helmut, Jagirdar, Kasturee, Atkinson, Victoria, Lambie, Duncan, Prow, Tarl W., Sturm, Richard A. and Soyer, Peter (2014). BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib. JAMA Dermatology, 150 (10), 1079-1082. doi: 10.1001/jamadermatol.2014.436

BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib

2014

Conference Publication

Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study

Martin-Algarra, Salvador, Cebon, Jonathan, Neyns, Bart, Brown, Ewan, Puertolas, Teresa, Garcia, Yolanda, Atkinson, Victoria, Crown, John, Lau, Mike, Dalland, Lindi, Stein, Dara, Payne, Krista, Aktan, Gursel, Jobanputra, Minesh, Queirolo, Paola and Millward, Michael (2014). Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study. Society for Melanoma Research, Zurich, Switzerland, November 2014. Hoboken, NJ United States: Wiley-Blackwell Publishing. doi: 10.1111/pcmr.12317

Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study

2014

Journal Article

Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review

Dzienis, Marcin and Atkinson, Victoria (2014). Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review. Melanoma Research, 24 (4), 349-353. doi: 10.1097/CMR.0000000000000068

Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review

2013

Conference Publication

Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013

Dzienis, Marcin Radoslaw and Atkinson, Victoria (2013). Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013. American Society of Clinical Oncology Annual Meeting, 2013, Chicago, IL United States, 31 May - 3 June 2013. Alexandria, VA United States: American Society of Clinical Oncology.

Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013

2013

Conference Publication

Single institution experience of Hyperthermic Intraperitoneal Chemotherapy

Xu, Wen, Sparks, David, Atkinson, Victoria, Joubert, Warren, Lutton, Nicholas and Meade, Brian (2013). Single institution experience of Hyperthermic Intraperitoneal Chemotherapy. Annual Scientific Meeting of Medical Oncology Group of Australia, Melbourme, Australia, August 2013.

Single institution experience of Hyperthermic Intraperitoneal Chemotherapy

2012

Conference Publication

Retrospective review of patients managed with chemotherapy for metastatic colorectal cancer at the Princess Alexandra Hospital

Ryan, C., Atkinson, V. and Klein, K. (2012). Retrospective review of patients managed with chemotherapy for metastatic colorectal cancer at the Princess Alexandra Hospital. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting, Queensland, Australia, 8 – 10 August 2012. Oxford, United Kingdom: Wiley-Blackwell Publishing.

Retrospective review of patients managed with chemotherapy for metastatic colorectal cancer at the Princess Alexandra Hospital

2011

Conference Publication

Single Institution Experience of the Stupp Protocol in Management of Glioblastoma Multiforme

Caird, Susan and Atkinson, Victoria (2011). Single Institution Experience of the Stupp Protocol in Management of Glioblastoma Multiforme. Annual Scientific Meeting of Medical Oncology Group of Australia, Adelaide, SA Australia, 10-12 August 2011. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/j.1743-7563.2011.01417.x

Single Institution Experience of the Stupp Protocol in Management of Glioblastoma Multiforme

Funding

Current funding

  • 2023 - 2026
    Assessment of tumour phenotype for precision medicine in oesophageal cancer via deep learning analysis of medical images
    CCQ Accelerating Collaborative Cancer Research
    Open grant
  • 2021 - 2025
    Novel predictive disease modelling using liquid biopsies to improve outcomes in melanoma (MRFF Genomics Health Futures Mission grant led by the University of Melbourne)
    University of Melbourne
    Open grant
  • 2020 - 2025
    Circulating tumour DNA guidEd Therapy for stage IIB/C BRAF mutant positive mElanoma after surgiCal resecTION (DETECTION) (MRFF ICTC led by University of Melbourne)
    University of Melbourne
    Open grant
  • 2018 - 2025
    A Randomised Phase III Study of the duration of the Anti-PD1 - therapy in metastatic melanoma (STOP-GAP)
    NHMRC Project Grant
    Open grant

Past funding

  • 2020 - 2021
    Cancer Evolution Biobank
    PA Research Foundation
    Open grant

Supervision

Availability

Professor Victoria Atkinson is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Professor Victoria Atkinson's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au